Sports
Pimicotinib Significantly Improved Outcomes For Patients With Tenosynovial Giant Cell Tumor In A Global Phase III Trial
(MENAFN - PR Newswire) – The MANEUVER study met the primary endpoint with an objective response rate (ORR) at week 25 of 54.0% compared with 3.2% for placebo (p< 0.0001 ) –– ...
By: menafn
- Nov 12 2024
- 0
- 0 Views
Share this page
Guest Posts by Easy Branches
